BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

375 related articles for article (PubMed ID: 8878460)

  • 1. Inhibition of growth and metastasis of ovarian carcinoma by administering a drug capable of interfering with vascular endothelial growth factor activity.
    Mu J; Abe Y; Tsutsui T; Yamamoto N; Tai XG; Niwa O; Tsujimura T; Sato B; Terano H; Fujiwara H; Hamaoka T
    Jpn J Cancer Res; 1996 Sep; 87(9):963-71. PubMed ID: 8878460
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor-derived vascular endothelial growth factor up-regulates angiopoietin-2 in host endothelium and destabilizes host vasculature, supporting angiogenesis in ovarian cancer.
    Zhang L; Yang N; Park JW; Katsaros D; Fracchioli S; Cao G; O'Brien-Jenkins A; Randall TC; Rubin SC; Coukos G
    Cancer Res; 2003 Jun; 63(12):3403-12. PubMed ID: 12810677
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment for malignant pleural effusion of human lung adenocarcinoma by inhibition of vascular endothelial growth factor receptor tyrosine kinase phosphorylation.
    Yano S; Herbst RS; Shinohara H; Knighton B; Bucana CD; Killion JJ; Wood J; Fidler IJ
    Clin Cancer Res; 2000 Mar; 6(3):957-65. PubMed ID: 10741721
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A defect in cell-to-cell adhesion via integrin-fibronectin interactions in a highly metastatic tumor cell line.
    Abe Y; Tsutsui T; Mu J; Kosugi A; Yagita H; Sobue K; Niwa O; Fujiwara H; Hamaoka T
    Jpn J Cancer Res; 1997 Jan; 88(1):64-71. PubMed ID: 9045898
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vascular endothelial growth factor activating matrix metalloproteinase in ascitic fluid during peritoneal dissemination of ovarian cancer.
    Yabushita H; Shimazu M; Noguchi M; Kishida T; Narumiya H; Sawaguchi K; Noguchi M
    Oncol Rep; 2003; 10(1):89-95. PubMed ID: 12469150
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of interferon alpha on vascular endothelial growth factor gene transcription and tumor angiogenesis.
    von Marschall Z; Scholz A; Cramer T; Schäfer G; Schirner M; Oberg K; Wiedenmann B; Höcker M; Rosewicz S
    J Natl Cancer Inst; 2003 Mar; 95(6):437-48. PubMed ID: 12644537
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Expression of vascular endothelial growth factor and its receptor (Flt-1) in breast carcinoma].
    Wu H; Li Y; Zhu G; Zhang L; Zhang X; He X
    Zhonghua Yi Xue Za Zhi; 2002 May; 82(10):708-11. PubMed ID: 12133473
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors.
    Petit AM; Rak J; Hung MC; Rockwell P; Goldstein N; Fendly B; Kerbel RS
    Am J Pathol; 1997 Dec; 151(6):1523-30. PubMed ID: 9403702
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Suppression of tumor angiogenesis and growth by gene transfer of a soluble form of vascular endothelial growth factor receptor into a remote organ.
    Takayama K; Ueno H; Nakanishi Y; Sakamoto T; Inoue K; Shimizu K; Oohashi H; Hara N
    Cancer Res; 2000 Apr; 60(8):2169-77. PubMed ID: 10786681
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration.
    Wood JM; Bold G; Buchdunger E; Cozens R; Ferrari S; Frei J; Hofmann F; Mestan J; Mett H; O'Reilly T; Persohn E; Rösel J; Schnell C; Stover D; Theuer A; Towbin H; Wenger F; Woods-Cook K; Menrad A; Siemeister G; Schirner M; Thierauch KH; Schneider MR; Drevs J; Martiny-Baron G; Totzke F
    Cancer Res; 2000 Apr; 60(8):2178-89. PubMed ID: 10786682
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting the tumor vasculature: inhibition of tumor growth by a vascular endothelial growth factor-toxin conjugate.
    Olson TA; Mohanraj D; Roy S; Ramakrishnan S
    Int J Cancer; 1997 Dec; 73(6):865-70. PubMed ID: 9399667
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Generation of a syngeneic mouse model to study the effects of vascular endothelial growth factor in ovarian carcinoma.
    Zhang L; Yang N; Garcia JR; Mohamed A; Benencia F; Rubin SC; Allman D; Coukos G
    Am J Pathol; 2002 Dec; 161(6):2295-309. PubMed ID: 12466143
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis.
    Warren RS; Yuan H; Matli MR; Gillett NA; Ferrara N
    J Clin Invest; 1995 Apr; 95(4):1789-97. PubMed ID: 7535799
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Frequent administration of angiogenesis inhibitor TNP-470 (AGM-1470) at an optimal biological dose inhibits tumor growth and metastasis of metastatic human transitional cell carcinoma in the urinary bladder.
    Inoue K; Chikazawa M; Fukata S; Yoshikawa C; Shuin T
    Clin Cancer Res; 2002 Jul; 8(7):2389-98. PubMed ID: 12114444
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vascular endothelial growth factor is an in vivo survival factor for tumor endothelium in a murine model of colorectal carcinoma liver metastases.
    Bruns CJ; Liu W; Davis DW; Shaheen RM; McConkey DJ; Wilson MR; Bucana CD; Hicklin DJ; Ellis LM
    Cancer; 2000 Aug; 89(3):488-99. PubMed ID: 10931447
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Constitutive upregulation of hypoxia-inducible factor-1alpha mRNA occurring in highly metastatic lung carcinoma cells leads to vascular endothelial growth factor overexpression upon hypoxic exposure.
    Koshikawa N; Iyozumi A; Gassmann M; Takenaga K
    Oncogene; 2003 Oct; 22(43):6717-24. PubMed ID: 14555985
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo activities of mutants of vascular endothelial growth factor (VEGF) with differential in vitro activities.
    Leenders W; van Altena M; Lubsen N; Ruiter D; De Waal R
    Int J Cancer; 2001 Feb; 91(3):327-33. PubMed ID: 11169955
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interleukin-8 and vascular endothelial growth factor mRNA and protein levels are down-regulated in ovarian carcinoma cells in serous effusions.
    Davidson B; Reich R; Kopolovic J; Berner A; Nesland JM; Kristensen GB; Tropé CG; Bryne M; Risberg B; van de Putte G; Goldberg I
    Clin Exp Metastasis; 2002; 19(2):135-44. PubMed ID: 11964077
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular mechanisms underlying IFN-gamma-mediated tumor growth inhibition induced during tumor immunotherapy with rIL-12.
    Yu WG; Yamamoto N; Takenaka H; Mu J; Tai XG; Zou JP; Ogawa M; Tsutsui T; Wijesuriya R; Yoshida R; Herrmann S; Fujiwara H; Hamaoka T
    Int Immunol; 1996 Jun; 8(6):855-65. PubMed ID: 8671675
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis.
    Rak J; Mitsuhashi Y; Bayko L; Filmus J; Shirasawa S; Sasazuki T; Kerbel RS
    Cancer Res; 1995 Oct; 55(20):4575-80. PubMed ID: 7553632
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.